Save Product
Product Details
Synonyms
MERTK, Mer
Source
Human MERTK, His Tag (MEK-H52H6) is expressed from human 293 cells (HEK293). It contains AA Ala 21 - Ile 505 (Accession # Q12866-1).
Predicted N-terminus: Ala 21
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 54.5 kDa. The protein migrates as 70-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human MERTK, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-SPR
Human MERTK, His Tag (Cat. No. MEK-H52H6) immobilized on CM5 Chip can bind Human GAS6, His Tag (Cat. No. GA6-H5249) with an affinity constant of 50.9 nM as determined in SPR assay (Biacore 8K) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Tyrosine-protein kinase Mer
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
8 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
